# Study of ART0380 in Patients With Biologically Selected Solid Tumors

> **NCT05798611** · PHASE2 · TERMINATED · sponsor: **Artios Pharma Ltd** · enrollment: 36 (actual)

## Conditions studied

- Advanced Solid Tumor
- Recurrent Endometrial Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** ART0380

## Key facts

- **NCT ID:** NCT05798611
- **Lead sponsor:** Artios Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-06
- **Primary completion:** 2024-11-15
- **Final completion:** 2025-05-27
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Sponsor decision, not for reasons affecting the benefit-risk balance.
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05798611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05798611, "Study of ART0380 in Patients With Biologically Selected Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05798611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*